NCT03344536View on ClinicalTrials.gov

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

November 10, 2017

Primary Completion Date

August 12, 2021

Study Completion Date

August 12, 2021

Conditions
Breast Cancer
Interventions
DRUG

Fulvestrant

Fulvestrant will be administered according to its approved dose of 500 mg intramuscularly on days 1, 15, 29 and then every 28 days (+/-3 days) thereafter.

DRUG

Debio 1347

Debio 1347 will be administered orally daily (1 cycle is 28 days) and the dose of Debio 1347 could be deescalated.

Trial Locations (1)

10065

Memorioal Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Debiopharm International SA

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER